Since the advent of precision instruments and safe techniques for direct laryngoscopic surgery under general anesthesia, indirect laryngeal surgery has become very uncommon. A review of the recent literaturefinds thatfew authors advocate indirect surgery under topical anesthesia, and many otolaryngologists dismiss this technique as being either of only historical interest or an idiosyncratic method practiced only by a handful of clinicians. The societal mandate for cost-effective healthcare and the availability of relatively low-cost, high-quality endoscopes and video equipment warrant a renewed and broader interest in this type of surgery. In this article, we review a series of 27 indirect surgical procedures performed under topical anesthesia in the clinical voice laboratory. We discuss the indications, outcomes, advantages, and disadvantages of this surgery, and we present a brief analysis of its cost-effectiveness. We conclude that indirect laryngeal surgery in the clinical voice laboratory is an effective, safe, efJicient, and less costly alternative to some procedures routinely pe$ormed under general anesthesia.
Introduction
The two options for evaluating laryngeal pathology are an indirect mirror examination and an examination by endoscopy. Flexible fiberoptic endoscopes are routinely used in the outpatient clinic setting, and the use of rigid laryngeal endoscopes with angled lenses is becoming more commonplace. Direct laryngoscopy under general anesthesia in the operating room is routine in most cases when a detailed examination, biopsy, injection, or excision of a laryngeal lesion is undertaken.
The history of laryngology, and in particular laryngoscopy, is a colorful one. A review of the early attempts to develop reliable instrumentation and techniques for visualization of the larynx reveals that there have been several creative pioneers. In the first half of the 19th century, Bozzini, Babbington, Desmormeaux, and others experimented with a variety of devices for laryngeal examination.' In 1854, voice teacher Manuel Garcia viewed the glottis by reflecting light off a dental mirror, and this led others to begin applying the laryngeal mirror in clinical examinations. Morel1 MacKenzie further broadened the horizons of laryngology when he developed instruments for indirect laryngeal surgery.
As a result, interest in laryngology rapidly expanded, and during the latter part of the 19th century, rigid instruments for direct laryngoscopy were introduced and refined by such renowned endoscopists as Chevalier Jackson. Improvements in instrument design and the development of safe techniques for general anesthesia eventually led to the point where direct laryngeal surgery in large part supplanted indirect laryngeal surgery.
Both technological advances and societal priorities warrant a renewed interest in indirect laryngeal procedures. Chief among these factors are the availability of high-quality and relatively affordable endoscopes and video equipment, and the quest for cost-efficient healthcare. There are also inherent advantages to performing certain laryngeal procedures when the patient is upright and awake, such as the ability to assess voice when performing injection laryngoplasty and to observe vocal fold mobility when staging a tumor.
Researchers at a small number of centers have recognized the intrinsic advantages of this approach and have recently published series of reports on indirect laryngeal and pharyngeal examinations and procedure^.*-^ These reports have helped document the safety and efficiency of these techniques. Even so, utilization remains limited, and these techniques are not routinely taught in residency training programs. Further study will be necessary before these techniques can become establi shed in the standard surgical armamentarium of the otolaryngologist-head and neck surgeon, rather than being considered nothing more than idiosyncratic methods employed by few practitioners.
The purpose of our report is to review a series of indi rect procedures and help furthe r define appropriate roles for these operations. We review the indic ations, outcomes, and comp lications of indirec t surgery, and we present a brief cost -compar ison analysis.
Materials and methods
Patients. We retrospectively reviewed the recor ds of all patie nts who had undergone indirect procedures in the clinical voice laboratory at the Universi ty of Mic higan from August 1995 through January 1999. In each case, we noted the indications, outcomes, and comp lications. We based our cost comparison on the experiences of two patients who had undergone an indirect biopsy shortly after a direct laryngoscopy and biop sy under general anesthesia. All patients had signed a standard operative permit , and this review was undert aken with the approval of the University of Michigan ' s Institutional Review Board.
Techniques. The techniques used for indirect laryngeal examination and surgery have been previously described.2.5
The main features of these indirect techniques incl uded the topical anes thetization of the oropharynx with 10% lidocaine spray, which was followed by an examina tion of the larynx and hypopharynx with a 70°rigid magnifyi ng laryngoscope (Kay Elemetric s; Lincoln Park, NJ) or a 90°i nstrume nt (Richard Wolf Medical Instruments; Vernon Hills, IIl.), attac hed to a com puter-i ntegrated videostroboscopy system (Kay Elemetrics). With the patient seated directly opposi te the examiner, the larynx, hypoph arynx , and trachea were anest hetized with a topical application of 4% lidocaine solution (figure I). As appropriate for the partic ular procedure, a standard flexib le laryngoscope could then be used for further exa mination around bulky lesions or into the pyriform sinuses or postcricoid region . When neces sary, light intravenous sedation with small aliquots (0.5-mg increments) of midazolam titrated to effect was admini stered to further suppress an active gag refle x during the anesthetization proce ss.
Once top ical anesthesia was sufficient and the initial examination was comp lete, the appropriate procedure was performed with the rigid magnifying laryngo scope and the videoendoscopy system. Biop sy specimens were take n with a curved laryngeal biopsy forceps . Scar division/excision was performed with the biopsy forceps , with or without an attached scalpel blade. Injection laryngoplasties employed a Bruening's press ure syringe with a curve d inje ction needle, and an orotracheal injec tion devic e was used for steroid injections of granu lomata and for collagen injec tion s. Figures 2A through 2C show the view through a 70°rigid endo scope during instillation of lidocaine , laryngeal biop sy, and injection laryngoplasty. Vital signs were monitored in patients who received light IV sedation. Patients were instructed not to eat or drink until normal sensation had returned to the larynx and phary nx.
Results
From August 1995 thro ugh Jan uary 1999, 27 indirec t procedures were performed in the clinical voice laboratory on 24 patie nts. Twenty-six procedures were on the larynx and one on an adjacent hypo pharyngea l lesion. They included 13 bio psies, eight injec tion laryngoplasties, three stero id injections, and three scar divisions/ exc isions.
The 13 biopsies were of lesions suspicious for squamous cell carcinoma (table I). The eig ht inject ion laryngoplasties were performed for the treatment of dysphonia second ary to unilateral vocal fold para lysis or voca l fold scarring; these eight cases included five Gelfoam injections, two Teflon injections, and one auto logous collagen injection. Three gra nulomat a were injected with steroid, and the three remaining procedures were performed to divide or excise posterior glott ic scarring caused by longterm intub ation. In one case, sca r treatment was performed as an adjunct to a recentl y completed procedure under general anesthesia. Three patients required light IV sedation.
Sixteen procedures were performed in the voice laboratory rather than under general anesthesia solely because of the authors ' preference for the efficiency and voice monitoring adva ntages of ope rating in the outpatien t clinic on an awake and upright patient. The other I I patients had been referred to the principal author by
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REPORTED colleagues because these patients had a variety of reasons to avoid general anesthesia: Six patients had significant medical comorbidities; three patients had persistent suspicious lesions despite recent inconclusive biopsies via direct laryngoscopy; one patient had undergone a previous, unsuccessful attempt at direct laryngoscopy and biopsy of an anterior glottic lesion (which was unsuccessful because of the inability to visualize the anterior larynx under general anesthesia); and a remaining private-pay patient was concerned about cost.
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Biopsies . All 13 indirect biopsies yielded adequate tissue for pathologic analysis. The diagnoses included six invasive squamous cell carcinomas, one carcinoma in situ, and one cellular atypia without frank carcinoma; five biopsies were negative (benign infectious or inflammatory lesions). The patient with cellular atypia was eventually found to have carcinoma in situ after undergoing a subsequent biopsy under general anesthesia. Prior to the indirect biopsy , this patient had already undergone an earlier biopsy under general anesthesia that was interpreted as carcinoma in situ despite the gross appearance of invasive squamous cell carcinoma.
Injection laryngoplasties. Seven of the eight injection laryngoplasties yielded satisfactory results. The remaining patient was schedu led for a repeat injection of Teflon because of a decline in voice strength in the months following the initial injection. It should be noted that laryngeal framework surgery and nerve transfer operations are the preferred methods of surgical rehabilitation of unilateral vocal fold paralysis at our institution.
We used the Teflon in two patients because one patient had metastatic lung carcinoma and a very limited life expectancy, and the other had extensive neck scarring from previous surgery and irradiation that precluded other options. Resu lts of the Gelfoam injec tions were considered satisfactory if the patient experienced an increase in voice strength for at least 6 weeks afterward. After 6 weeks, a decline in strength is expected as the material is resorbed. The patient who was injected with auto logous collagen experienced a sustained improvement in perceptual voice qua lity and voice-related quality of life (V-RQOL), as determined by the V-RQOL measure," at 14 months postinjection.
Steroid injections. Steroid injections were accomplished satisfactorily in all three patients, althoug h one of the treated granu lomata persisted despite antireflux measures and voice therapy .
Scar division/incision. Two of the three cases of pos terior glottic scarring featured mature interarytenoid adhesion bands with obvious mucosally lined tracts posteriorly. These bands were easily divided, and the scar remnants were removed with cup forceps. Both patients had an improved airway and required no additional procedures.
The third patient had more extensive posterior commissure and interarytenoid scarring. Examination in the clinic had demonstrated that this woman had bilateral vocal fold motion impairment caused by scarring, but it was unclear from that examination whether a mucosa lly lined tract existed posteriorly. She was taken to the operating room for a micro laryngoscopy I week prior to the indirect procedure, and examination under general anesthesia demonstrated scarring that had a mucosally lined trac t posteriorly for most but not all of the inferior -to-superior length of the scar. Based on these findings, we felt that HOGIKYAN, PYNNO NEN No. patients Procedure
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The utility of these techniques for the individual surgeo n will differ accordin g to practice pattern s, trainin g, availability of instrumentation, and individual preferences regarding the roles for such opera tions. This series reflects the diversity in their utility, in that although the principal author performed all the procedu res, our patients ca me from the practices of seve ral different physicia ns, both inside and outside our insti tution.
Vario us contra indications to general anesthesia were the basis for em ploying the indirec t proce dure for all but one of the 11 patients who had been referred by other surgeons. In the other 16 cases, indirect procedures were performed on patients in the author's own practice, and this was done solely beca use of the recognized advantages that they have over direct procedures .
The most obvio us adva ntage to using indirect techniques is the relative efficiency in expedi ting a diagnosis and, in some cases, treatment. Avoidance of genera l anesthesia and its associated risks is another good reaso n to consider an indirect approac h. Th is is true for any patient, but in part icular for those who have relative or absolute contr aind ication s to genera l anest hesia.
There was only one significa nt complication in our series-delaye d postoperative bleedin g-but it was not considered to be directly related to the techniqu e. For injec tion laryngopl asty, there is no doubt that the ability to active ly assess the voice while the patien t is upright and awake holds inherent adva ntages over the same procedure in a patie nt who is asleep and supine . Finally, although comparison data were available for only two patients, the potential cos t savi ngs are compelling.
Discussion
Historically, indirect laryngeal surgery was pioneered long before the development of adequa te instrument ation and safe tech niques for direct laryngoscopy and general anesthesia . Some modern practitioners might feel that the indirect techniqu es are only of historica l interes t. To the contrary, we cons ider them to be a lost art. Familiarity and facili ty with indirect laryngeal procedures can be a very valuable asse t for the contemporary otolaryngologist-head and neck surgeo n. Thi s article provides ev idence of the safety and versatility of these techniques, and it touches on the potentially large cost savings compared with similar direct laryngo-Total scopic procedur es. division of the scar in the midl ine with a CO 2 laser was a reasonable initial attempt at treatment, and this did improve her passive arytenoid mob ility intraoperatively. At the l-week followup appointment, we observed that the patie nt had developed adhesio ns in the area of the scar division, and these adhesio ns were divided with an ang led force ps and the indirect technique. The woma n ex per ienced a subjective and visible improvement in her glott ic airway fro m the combined treatment, and she was able to have her perioperative tracheotomy decannul ated once the posterior glottis was completely healed.
All 27 proce dures were generally well tolerated. Coughing was routinely encountered during the initial instillation of topic al anesthetic, and sometimes dur ing the latter stages of a procedure. No patient suffere d laryngospasm . Patients were ge nerally tolerant of the small amounts of blood-tinged sputum following most proce dures and the pulling sensations experienced dur ing some biopsies.
There was one significant complica tion, which occurred in a man who had undergone a biopsy of a large suprag lottic mass. Approximately 24 hours followi ng this procedure, he began to bleed from the biopsy site. In light of the bleedi ng and the large size of his supraglottic tumor, he underwe nt an urgent tracheotomy for airway management. The bleeding itself did not require further intervention, and the patient' s subseq uent defi nitive oncologic treatment outcome was not affec ted by the episode.
Cost comparison. Two patients in this series were biopsied in the voice laboratory shortly after they had undergone unsatisfactory biopsy proce dures via direc t laryngoscopy under general anest hesia. These two cases allowe d us to make a cost comparison of the two modalities (table 2) . As expected, the indirect procedures were co nsidera bly less expensive because there were no anesthesio logis t, operating room, or recovery room costs. Since thiseffect mayalso occur with amoxicillin andtherefore Augmentin, it is recommended that glucose tests based onenzymatic glucose oxidase reactions (such asCtinistix" or Ies-Iepe"l beused.
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INDIRECT LARYNGEAL SURGERY IN THE C LINICA L VOICE LABORATORY: THE RENEWAL OF A LOST ART Indirect laryngeal proc edures do have their limitations, althou gh they will likely be defined differ ently by each practit ioner. We do not feel that excision of true vocal fold lesions or biopsy of suspicious sessile true vocal fold lesion s should be appro ached in the indirect manner becau se the depth of the excision and the protect ion of adjacent mucosa are not adequately controlled . Microdirect laryngoscopy is preferred for such procedures. Also, although excellent tumo r staging can be accomplished in most patients with a rigid or flexibl e endoscope unde r adequate topical anesthesia,' the inferior extent of some lesions in the hypoph arynx can be difficult to assess in the voice laboratory. Evaluation of the esophagus is also deferred to the radiology suite or to the onset of a later surgical procedure for definiti ve lesion mana gemen t. Other limit ations include the fact that (1) there is a learnin g curve associated with becom ing proficient at voice laboratory procedures, (2) proper instrumentation is not always available, and (3) some patient s will simply prefer general anesthe sia.
In conclu sion, we believe that indirect laryngeal procedure s in the clinical voice laboratory are an effective, safe, efficient, and less costly alternative to some procedures routin ely performed via direct laryn goscop y under general anesthes ia. Although the utility of these techniques will vary by surgeon, the ability to perform indir ect procedur es would be a valuabl e component of the surgical armamentarium of every cont emporary otolaryngologisthead and neck surgeon. For mo re info rmatio n Circle 107 on Reader Servic e Card
